SCHEMBL675633

SCHEMBL675633

CCCCCC(=O)OC(C)C(=O)OC(C)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
ALDH1A1 P00352 1/20 0.51
MAPT P10636 2/20 0.50
MAPK1 P28482 1/20 0.50
PRKCA P17252 1/20 0.47
PRKCE Q02156 1/20 0.47
PRKCQ Q04759 1/20 0.47
PRKCD Q05655 1/20 0.47
PAM P19021 2/20 0.47
DGKA P23743 1/20 0.47
KDM4E B2RXH2 1/20 0.46
DUSP3 P51452 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30104654 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL465547 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL19821495 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL465544 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL18206768 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL465548 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL454068 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL19821494 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL19931336 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA
SCHEMBL30104686 0.98 LMNA (0.61) LMNAALDH1A1MAPTMAPK1PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021098950-A1 HOME CARE PRODUCT OR FORMULATION SYMRISE AG (DE) 2021-05-27 WO claimed
EP-1216036-B1 TRANSDERMAL ADMINISTRATION OF N-(2,5-DISUBSTITUTED PHENYL)-N'-(3-SUBSTITUTED PHENYL)-N'-METHYL GUANIDINES ALZA CORP (US) 2005-11-16 EP claimed
EP-0934078-B1 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORP (US) 2002-12-18 EP claimed
EP-0828516-B1 SKIN PERMEATION ENHANCER COMPOSITIONS USING ACYL LACTYLATES ALZA CORP (US) 2002-03-27 EP claimed
EP-0976391-A1 Cosmetic and dermatological W/O emulsions, containing ionic and/or amphoteric detergents and the presence of an amount of silicone-emulgators Beiersdorf Aktiengesellschaft (DE) 2000-02-02 EP claimed
US-20240239730-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-07-18 US disclosed
EP-4389765-A2 METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER University of Southern California (US) 2024-06-26 EP disclosed
US-11970436-B2 Pharmaceutical compositions comprising monoterpenes UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2024-04-30 US disclosed
EP-4041412-B1 CLEANSING PREPARATION CONTAINING CAESALPINIA SPINOSA GUM BEIERSDORF AG (DE) 2024-04-24 EP disclosed
EP-3749291-B1 METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER UNIV SOUTHERN CALIFORNIA (US) 2024-01-03 EP disclosed
US-20230405125-A1 TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL Neonc Technologies, Inc. 2023-12-21 US disclosed
EP-4279058-A1 PREPARATION OF A COSMETIC CLEANSING COMPOSITION Beiersdorf AG (DE) 2023-11-22 EP disclosed
EP-0976391-A1 Cosmetic and dermatological W/O emulsions, containing ionic and/or amphoteric detergents and the presence of an amount of silicone-emulgators Beiersdorf Aktiengesellschaft (DE) 2000-02-02 EP disclosed
EP-0943313-A2 Hair cosmetics containing sunflower wax and possibly jojoba wax Beiersdorf Aktiengesellschaft (DE) 1999-09-22 EP disclosed
WO-1999045055-A1 SULFONATED COMB POLYMERS AND PREPARATIONS, ESPECIALLY HAIR COSMETIC PREPARATIONS BASED ON SUCH SULFONATED COMB POLYMERS BEIERSDORF AG (DE) 1999-09-10 WO disclosed
EP-0937454-A2 Cosmetic or dermatological compositions containing polysaccharides for the protection of sensitive skin against irritations Beiersdorf Aktiengesellschaft (DE) 1999-08-25 EP disclosed
EP-0562263-B2 Hair washing composition GOLDWELL GMBH (DE) 1999-02-03 EP disclosed
EP-0535429-B1 Hair spray composition GOLDWELL AG (DE) 1994-12-14 EP disclosed
EP-0562263-A1 Hair washing composition GOLDWELL GmbH (DE) 1993-09-29 EP disclosed
EP-0535429-A2 Hair spray composition GOLDWELL AKTIENGESELLSCHAFT (DE) 1993-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239730-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES SQLE, DHPS, GGPS1 LMNA 907/4885ALDH1A1 793/4885MAPT 1232/4885
US-11970436-B2 Pharmaceutical compositions comprising monoterpenes SQLE, DHPS, GGPS1 LMNA 907/4885ALDH1A1 793/4885MAPT 1232/4885
US-20230405125-A1 TREATMENT OF RECURRENT GIOBLASTOMA WITH PERILLYL ALCOHOL IDH3A, IDH1, IDH3B LMNA 2055/4885ALDH1A1 162/4885MAPT 4280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.